Met Life Investment Management, LLC Editas Medicine, Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 38,517 shares of EDIT stock, worth $100,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,517
Previous 51,955
25.86%
Holding current value
$100,144
Previous $114,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
48 transactions
Others Institutions Holding EDIT
# of Institutions
227Shares Held
46.2MCall Options Held
841KPut Options Held
304K-
Black Rock Inc. New York, NY7.78MShares$20.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.97MShares$18.1 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC2.09MShares$5.44 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$5.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.93MShares$5.01 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $179M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...